Author: admin

  • Why Alpine have enquired about Mercedes reserve Valtteri Bottas’ availability

    Why Alpine have enquired about Mercedes reserve Valtteri Bottas’ availability

    Alpine have enquired about the availability of 10-time race winner and current Mercedes reserve Valtteri Bottas, should they decide they want to change their line-up this season or beyond. F1 Correspondent Lawrence Barretto explains the state of play…

    Why are Alpine looking for a driver if they already have Gasly and Colapinto locked in this season?

    Well, they’re not so much chasing as they are exploring their options.

    Alpine are in something of a transitional year – and with the Enstone-based team swapping to Mercedes power next year as part of an overhaul of the squad under the stewardship of Flavio Briatore, they are keen to get their driver line-up right for 2026.

    Pierre Gasly is, without question, part of their plans. Their second seat is trickier.

    They’ve already made a change this season, bringing in Franco Colapinto to replace Jack Doohan (with the latter back to reserve and the bench) from Imola onwards.

    Colapinto hasn’t hit the ground running like he did in his super sub performance for Williams and has yet to score a point in five races with the squad.

    However, it must be said that the car has lacked performance relative to its rivals and, since Colapinto joined the team, his team mate Gasly has scored just once with eighth in Spain.

    Alpine continue to back Colapinto – and believe he is capable of delivering.

    But as 2026 edges ever closer, Briatore is doing what you’d expect him to do – keeping his finger on the pulse and ensuring he knows what his options are going forward, hence why sources say he contacted Mercedes to check on Bottas’ availability.

    So, don’t leave me hanging – what did they say?

    My understanding is that Mercedes will not stand in Bottas’ way should he be offered a race seat elsewhere.

    I believe Bottas is contracted to the Silver Arrows, where he won all of his 10 races, until the end of the year – and then he is free to make his own decisions with regards trying to find a race seat (or worst-case alternative role) next season.

    His boss Toto Wolff is a big supporter of Bottas and believes he is still operating at a high-level and is deserving of a place on the grid. So, it’s no surprise they would accommodate a request should one be made for his services, especially as Alpine will be running the Silver Arrows’ engines next year.

    Why would Alpine be keen to explore an option on Bottas?

    It’s two-fold. Briatore finds the team’s currently level of performance concerning. With Alpine locked to the bottom of the Constructors’ Championship, he wants short-term progress soon.

    Having two strong drivers delivering consistently can have a significant impact – as Williams are seeing with their experienced line-up of Alex Albon and Carlos Sainz.

    Secondly, he wants the team to take advantage of sweeping changes to the aerodynamic and power unit regulations next season – and the arrival of Mercedes power, which is widely expected to be among the best, if not the best, engines next year.

    Bringing on someone with Bottas’ experience could help on both counts.

    The Finn has 247 Grands Prix to his name, has won 10 races, scored 67 podiums and taken 20 pole positions. He excelled during his time at Mercedes, particularly with regards to his one-lap pace, and made a positive impact during his three years at Sauber.

    His time at Mercedes has given him recent insight into how a race-winning team is operating while he is believed to have been fully plugged into the development of the 2026 car. He even had some seat time with McLaren earlier this year in a 2023-spec car.

    Alpine could benefit from Bottas’ presence in the race team – and there will be those internally who are fans of his given he was in contention for a seat there this year before the management changed and opted for Doohan.

    Will Bottas fancy it?

    One thing is for sure, Bottas is hungry to return to a race seat and more motivated than ever.

    He took the Mercedes reserve role (to stay relevant, fit and connected to the sport) and is keen on discussions with newcomers Cadillac about a race seat next year.

    The Finn would back himself to deliver if he gets a shot at Alpine – and you’d expect he’d be interested in a deal that allows him to drive next year, too, for security. His experience with Mercedes power could be invaluable.

    Such a move would help him get race sharp again so that even if Alpine don’t retain him, he would be even more appealing to the likes of Cadillac, as they look to hit the ground running on debut next year.

    So, now what happens?

    For now, it’s business as usual and Colapinto will be in the car at Silverstone and beyond.

    If Alpine decide they want to pursue an alternative, preliminary talks with Mercedes would likely continue, with Bottas and his management also being drafted in if things accelerate.

    This situation must be tough on Colapinto…

    Absolutely, but every driver is under pressure to perform – and Colapinto is no different.

    Briatore’s move to explore options will raise that pressure, but it might trigger a step up in performance for the Argentine driver.

    Silverstone is a circuit which the 22-year-old has performed well at in junior formulae – and he’ll have fond memories of the place having made his Grand Prix weekend debut there last year when driving for Williams.

    If Colapinto improves his results, Briatore won’t need to change anything for now. And just knowing Bottas is available gives Briatore and Alpine flexibility.

    Continue Reading

  • Watch: Vaibhav Suryavanshi heaves fire with bat; India yet fall short as England level series 1-1 | Cricket News

    Watch: Vaibhav Suryavanshi heaves fire with bat; India yet fall short as England level series 1-1 | Cricket News

    Vaibhav Suryavanshi of India (Photo by Michael Steele/Getty Images)

    NEW DELHI: Despite another solid knock of 45 runs from opener Vaibhav Suryavanshi, India fell agonizingly short as England edged a dramatic one-wicket victory in the second Youth ODI at Hove on Monday, levelling the five-match series 1-1. India had entered the match on a high after their commanding win in the opener, where Suryavanshi top-scored with 48. Go Beyond The Boundary with our YouTube channel. SUBSCRIBE NOW!The young right-hander continued his fine form, scoring a composed 45 to help India recover from a disastrous start after skipper Ayush Mhatre was dismissed for a golden duck.

    Late selection meeting between Gautam Gambhir, Shubman Gill and Ajit Agarkar near pitch?

    Watch: Alongside Suryavanshi, Vihaan Malhotra (49), Rahul Kumar (47), Kanishk Chouhan (45), and Abhigyan Kundu (32) all chipped in with useful contributions, guiding India to a competitive total of 290 in 49 overs. England’s bowlers were far from disciplined, leaking 32 extras, including a staggering 26 wides. Still, AM French led the way with 4 for 71, while Jack Home (3/63) and Alex Green (3/50) shared the rest of the spoils. The chase, however, proved to be a rollercoaster. England stumbled early at 7 for 1 and later 47 for 3, with medium pacer RS Ambrish striking twice in quick succession.

    Poll

    Do you think India’s batting lineup can bounce back in the next match?

    But a magnificent counterattack from England captain Thomas Rew, who hammered 131 off just 89 balls (16 fours, 6 sixes), turned the tide. His 123-run stand with Rocky Flintoff (39) laid the foundation, but once Rew fell in the 40th over, the match swung back toward India. With England reduced to 254 for 8 by the 46th over, Ambrish (4/80) reignited hopes for India. England needed seven off the final over, and with only one wicket in hand, the game hung on a knife’s edge. But Sebastian Morgan (20 not out) held his nerve, striking a boundary off the third ball of Yudhajit Guha’s over to seal a heart-stopping win. Though India were left to rue missed chances, Suryavanshi’s consistency at the top continues to be a bright spot. As the series heads into the third match, India will look to regroup and lean on their in-form opener to regain the lead.


    Continue Reading

  • Q2 2025 Recap: Ophthalmology News and Updates

    Q2 2025 Recap: Ophthalmology News and Updates

    Ophthalmology has been on a tremendous rise in recent years, with developments on almost every front and new treatments for a slew of diseases. Upcoming therapies and groundbreaking technology have paved the way for attempts to lighten the treatment burden on patients by extending dosing intervals; a number of medications have exhibited efficacy outside of their expected field in ophthalmology; and trial successes have come hard and fast.

    Q2 2025 followed many of these patterns, with the US Food and Drug Administration (FDA) handing out approvals to several critically important medications and companies worldwide announcing successful advancements on first-of-their-kind drugs. Niches were filled, treatment burdens were lessened, and alternative therapies were discovered. To mark the end of Q2 2025, HCPLive Ophthalmology created a recap of the biggest news from April to June 2025.

    This recap collects 5 regulatory updates from the FDA, our 5 biggest trial announcement articles, and 3 critical insights from top experts featured prominently within our coverage.

    Q2 2025 Regulatory Updates in Ophthalmology

    FDA Issues Complete Response Letter to Aflibercept 8 mg for Extended Dosing

    Announced on April 18, this CRL was specifically for parent company Regeneron’s proposed dosage extension up to 24-weeks. No safety or efficacy issues of aflibercept 8 mg in any of its approved dosing regimens or indications were found; the FDA disagreed instead with an attempt to extend dosing intervals longer than the current maximum of 16 weeks according to the label.

    FDA Approves Prednisolone Acetate Ophthalmic Suspension for Ocular Inflammation

    On June 12, 2025, the FDA approved the sterile, topical anti-inflammatory agent for the treatment of steroid-responsive ocular inflammation. The medication is a self-administered eye drop intended for use 2-4 times daily. In addition to this approval, parent company Amneal Pharmaceuticals announced a planned launch for the third quarter of 2025.

    FDA Approves Acoltremon Ophthalmic Solution (TRYPTYR) for Dry Eye Disease

    On May 28, 2025, the FDA approved acoltremon, a first-in-class transient receptor potential melastatin 8 channel receptor agonist which stimulates corneal sensory nerves, to treat dry eye disease. Both pivotal phase 3 trials, COMET-2 and COMET-3, displayed rapid onset and sustained tear production, as well as a substantial percentage of patients with a ≥10mm increase in unanesthetized Schirmer’s score across both trials compared to vehicle.

    FDA Approves Susvimo for Treatment of Diabetic Retinopathy

    Announced on May 22, 2025, this approval marked the third approved indication for Susvimo, along with diabetic macular edema. The medication was made available to US retina specialists from the day that parent company Genentech announced the FDA approval. Susvimo is now the first and only FDA-approved continuous delivery treatment able to maintain vision in people with diabetic retinopathy with only 1 refill every 9 months.

    FDA Grants IND Clearance to Immunoglobulin Eye Drops for Dry Eye Disease

    On May 21, 2025, the FDA granted Investigational New Drug clearance to Selagine, Inc.’s immunoglobulin drops, an anti-inflammatory and immunomodulatory biologic drug for the treatment of dry eye disease. Selagine and partner Grifols, one of the leading producers of plasma-derived medicines, expect that the IG drops will reach retail pharmacies in early 2029.

    Q2 2025 Trial Announcements in Ophthalmology

    VVN461 Trial Topline Results Announced for Non-Infectious Anterior Uveitis

    Announced April 24, 2025, VivaVision announced that both VVN461-1.0% and VVN461-0.5% showed non-inferior efficacy against a prednisolone acetate comparator cohort in treating NIAU. Although VivaVision is based in China, the company has announced its intention to request a type C meeting with the FDA regarding phase 3 trials and an eventual BLA.

    Pegcetacoplan Reduces Rate of Geographic Atrophy Growth, 1-Year Trial Data Shows

    On April 23, 2025, 12-month results from the ongoing GALE open-label extension study indicated pegcetacoplan’s ability to reduce the mean rate of geographic atrophy growth. Initiated in response to positive results from the 2-year OAKS and DERBY trials of pegcetacoplan in patients with GA secondary to AMD, GALE is expected to significantly advance the evidence for the medication’s long-term safety and efficacy by its culmination.

    Oral Zervimesine Reduces Geographic Atrophy Lesion Growth in Phase 2 Trial

    Announced by Cognition Therapeutics on May 8, 2025, the phase 2 MAGNIFY trial resulted in oral zervimesine reducing lesion growth in patients with geographic atrophy secondary to age-related macular degeneration. Simultaneously being developed for Alzheimer’s and dementia with Lewy bodies, the once-daily oral pill may overcome the limitations of current treatment options, which require regular intravitreal injections.

    Veligrotug Shows Durability for Thyroid Eye Disease in Phase 3 Trial Results

    Long-term data announced on May 20, 2025, by Viridian Therapeutics, Inc. indicated the positive long-term durability of veligrotug in treating thyroid eye disease. Veligrotug, already granted the Breakthrough Therapy designation by the FDA prior, is also on track with its BLA planned for the second half of 2025.

    Opthea Announces Termination of ShORe and COAST Trials of Sozinibercept

    On April 2, 2025, Opthea announced the termination of their ShORe and COAST trials after sozinibercept failed to achieve vision improvement benchmarks in treating wet AMD. COAST failed on March 24, which led Opthea to accelerate topline data of the ShORe trial. However, when this trial also missed its benchmarks, Opthea shuttered the trials.

    Q2 Expert Perspectives in Ophthalmology

    Phase 2 LUNA Trial Results for Ixo-vec to Treat Neovascular AMD with Dante Pieramici, MD

    Dante Pieramici, MD, assistant clinical professor of ophthalmology at the Doheny Eye Center in Southern California, discusses the results of the phase 2 LUNA trial of ixoberogene Soroparvovec intravitreal gene therapy for the treatment of neovascular age-related macular degeneration.

    Changing Dosage Regimens in Patients with Diabetic Macular Edema, with Mark Barakat, MD

    Mark Barakat, MD, founder and director of research at the Retina Macula Institute of Arizona, discusses his post-hoc analysis examining the shortening or extending of aflibercept 8 mg dosage for patients with DME through week 96 of the PHOTON trial.

    Switching to Aflibercept 8 mg in Treatment-Experienced Patients with Ted Leng, MD

    Theodore Leng, MD, Director of Clinical and Translational Research and Director of Ophthalmic Diagnostics at the Stanford University School of Medicine, discusses the process of switching to aflibercept 8mg from other anti-VEGF agents in patients with neovascular age-related macular degeneration.

    Continue Reading

  • Invention improves ‘gene gun,’ targets efficiency gains in plant research

    Invention improves ‘gene gun,’ targets efficiency gains in plant research

    AMES, Iowa – Plant scientists have used a standard “gene gun” since 1988 to genetically modify crops for better yield, nutrition, pest resistance and other valuable traits.

     

    That technology, which loads genetic materials on tiny particles and uses high pressure to shoot them into plant cells, has presented challenges to plant scientists, including inefficiency, inconsistency and even tissue damage caused by high-velocity particles.

     

    But that was just the way these experiments worked, and plant scientists worked around the challenges.

     

    “We didn’t even know we had a problem,” said Kan Wang, an Iowa State University agronomist and Charles F. Curtiss Distinguished Professor in Agriculture and Life Sciences.

     

    Shan Jiang, an Iowa State associate professor of materials science and engineering, wondered if his research group could do something to improve that basic tool of plant research. Ultimately, he and the group determined plant scientists had been “shooting a bullet without a barrel” for 40 years.

     

    A paper just published by the journal Nature Communications details the research team’s search for a solution, its subsequent findings and the invention that launched a startup company.

     

    The project was more than solving a single engineering problem, though. Jiang, because of his research resume, really wanted to use his engineering approach to improve plant science and, potentially, human lives.

     

    Post-doc lessons

    After earning his doctorate from the University of Illinois Urbana-Champaign, Jiang went to work as a post-doctoral researcher in the Langer Lab at the Massachusetts Institute of Technology.

     

    That’s the lab of Robert Langer, once called the “smartest man in Boston” by the Boston Globe and co-founder and, until last August, a board member for Moderna, Inc., a leader in the creation of mRNA medicine, including vaccines for COVID-19.

     

    Jiang was one of 15 post-docs working on new ideas to deliver genetic materials for medical therapies.

     

    “It was such difficult research,” he said.

     

    But one outcome, even after research funding dried up, was the use of messenger RNA to produce proteins that could help the body fight off disease.

     

    “That research had a profound impact in my life,” Jiang said. “When I arrived at Iowa State, I thought about what I wanted to do.”

     

    But there was no research hospital and limited opportunities for medical research.

     

    He looked around in the scientific literature and read about delivering DNA into plant cells to introduce or boost particular traits, including high crop yields, resistance to insects or tolerance of heat.

     

    He picked up the phone and made a cold call.

     

    Wang answered and was surprised to be talking to a materials engineer but was interested enough to schedule a lunch and talk about the challenges of plant science research, particularly the challenge of delivering genetic materials through a plant’s tough cell walls.

     

    “It was such an overlooked area,” Jiang said. “Very few materials scientists were working on plant cell delivery. Agriculture is always overlooked – people want to cure cancer.”

     

    From losing patience to a shock discovery

    The decades-old “gene gun” used by plant scientists for what’s known as “biolistic” delivery of genetic information works by coating gold or tungsten microparticles, just a few millionths of a meter in size, with genetic material and then shooting particle and cargo into plant cells.

     

    Some of those cells survive the particle bombardment, take up the introduced DNA and express the corresponding traits. Whole plants can then be grown from the transformed cells.

     

    “However, biolistic delivery faces notable challenges with efficiency, consistency, and tissue damage caused by high-velocity microprojectiles, which hinder regeneration and transformation,” Jiang and co-authors wrote in their paper about the project (see team and paper details below). “Additionally, it often leads to fragmented and multiple transgene insertions in the genome, resulting in unpredictable gene expression.”

     

    Jiang and his research collaborators began looking for solutions – “We tried to minimize the error bar,” he said.

     

    The researchers tried everything they could think of, but Jiang said they made little progress. After four years, it was time to reconsider the time and effort spent on the project.

     

    “We were losing hope and patience,” Jiang said.

     

    In one last push for a solution, the research team ran computational fluid dynamics models of gene gun particle flows and discovered a bottleneck within an internal barrel. It seemed too narrow and restrictive, leading to particle loss, disrupted flow, decreased pressures, slower speeds, and uneven distribution at the target cells.

     

    “These findings pinpoint critical limitations in the gene gun design and led us to hypothesize that engineering the flow dynamics within the gene gun could significantly improve its efficiency and consistency,” Jiang and his collaborators wrote.

     

    To do that, the researchers designed a new internal barrel for the gene gun – they call it a “Flow Guiding Barrel” – and Connor Thorpe, a doctoral student and 3D-printing hobbyist, printed one for testing.

     

    “It improved performance by 50%, then two, three, five, ten, twenty times,” Jiang said. “I was very shocked, to be honest with you.”

     

    Easier plant transformations

    The computer modeling shows a conventional gene gun directs about 21% of loaded particles toward its plant cell targets while a gene gun modified with the Flow Guiding Barrel delivers nearly 100%.

     

    Subsequent tests by plant scientists found, for example, a 22-fold increase in transient transfection efficiency in tests with onions, a 17-fold improvement in viral infection efficiency in maize seedlings and double the efficiency of experiments using CRISPR genome editing tools in wheat.

     

    “No previous device has achieved such improvements, offering substantial potential for advancing genotype independent transformation and genome editing for plants,” paper co-authors wrote.

     

    Wang, the Iowa State plant scientist originally approached by Jiang, noted laboratory “improvements of 10-fold and sometimes 20-fold. We’re able to work far more efficiently.”

     

    Yiping Qi, a professor of plant science and landscape architecture at the University of Maryland and a project collaborator, said the Flow Guiding Barrel “will make plant transformation and genome editing easier with improved efficiency.”

     

    In one test, for example, he said the Flow Guiding Barrel allowed CRISPR reagents to penetrate deeper into the shoot apical meristem of bread wheat, the part of the plant where cell and leaf production occur.

     

    “This translated to the higher efficiency of heritable genome editing in the next generation of wheat,” Qi said. “While this demonstration was done in wheat, one can envision such improvement can also benefit other crops, like barley, sorghum, etc.”

     

    Support for research and development of the Flow Guiding Barrel came from Iowa State sources, including the Digital and Precision Agriculture Research and Innovation Platform; The Agriculture and Food Research Initiative of the U.S. Department of Agriculture’s National Institute of Food and Agriculture; the National Science Foundation; and the Department of Energy.

     

    A startup for plant science

    The Flow Guiding Barrel worked so well, Jiang; Thorpe; Wang; Kyle Miller, a former doctoral student in Jiang’s lab; and Alan Eggenberger, an Iowa State research scientist in materials science and engineering; took steps to investigate the commercial potential of the invention. Jiang and Thorpe also enrolled in Iowa State’s startup programs and later co-founded a company with Jibing Lin, an Iowa State graduate and startup leader. The U.S. Department of Energy’s Small Business Technology Transfer program has supported the company’s development.

     

    “This project would not be possible without close collaboration with plant biologists,” Jiang said. “We believe the best way to give back is to make our tools commercially available so they can be broadly used in the plant science community.”

     

    The Iowa State University Research Foundation filed for patent protection on the innovation and has licensed the commercial rights to the co-founders’ company, Hermes Biomaterials Inc. The company is based at the Iowa State University Research Park and is manufacturing its products in Iowa. The company continues its customer discovery work based on the National Science Foundation’s Innovation Corps program and has started selling products.

     

    With efficiency gains of 10- and 20-fold, Jiang said the Flow Guiding Barrel could save plant scientists and agriculture companies millions of dollars in time and plant or product turnaround.

     

    “This is a small device, and it seems overly simple,” Jiang said. “But the benefits it can bring are invaluable. It enables the development of safer and more effective strategies to improve crops that can better withstand environmental changes, enhance nutritional content, and contribute to sustainable energy production.”

     

    – 30 –

     

    The research team

    Iowa State University Materials Science and Engineering: Shan Jiang, Connor Thorpe, Alan Eggenberger, Ritinder Sandhu

    Iowa State Agronomy and Crop Bioengineering Center: Kan Wang, Qing Ji, Keunsub Lee, Steven Whitham

    Iowa State Plant Pathology, Entomology and Microbiology: Aline Chicowski, Weihui Xu

    University of Maryland Plant Science and Landscape Architecture: Yiping Qi, Weifeng Luo

     

    Read the paper

    “Enhancing biolistic plant transformation and genome editing with a flow guiding barrel,” Nature Communications, July 1, 2025, https://doi.org/10.1038/s41467-025-60761-x


    Continue Reading

  • Scooter Braun Exits CEO Role at HYBE, Settles With Justin Bieber

    Scooter Braun Exits CEO Role at HYBE, Settles With Justin Bieber

    Scooter Braun is transitioning his role at HYBE, the South Korean entertainment giant, moving from CEO of HYBE America to an advisory position which will have him joining the HYBE Board of Directors as a director and a senior advisor to chairman and CEO Bang Si-Hyuk. The move marks the end of a five-year run at HYBE, which is home to such K-pop acts as BTS and Katseye.

    The news was announced to HYBE staffers on Monday when Braun, dialing in from David Geffen’s yacht where he is vacationing, notified employees that the move was “in the works for quite some time,” according to a source who adds that the five-year plan was initiated with the sale of Braun’s Ithaca Holdings to HYBE in 2021. Braun will remain active in current HYBE projects, like the just-launched girl group Katseye. Braun intimated that he “isn’t going anywhere” and will “still help guide” the artists on the HYBE roster. During the call, Braun shared with the staff that, when he set out for a career in music 25 years ago, it was after reading the Geffen biography The Operator. Today, as he closes this chapter of his career, he reminded his colleagues of what he’s learned from Geffen: “Follow your dreams and anything can happen.”

    Braun built his business managing music artists like Justin Bieber, Ariana Grande, J Balvin, Demi Lovato and The Kid LAROI under the SB Projects banner. In 2024, he stepped away from the management business, announcing his decision on social media, where he noted, “I have been blessed to have had a ‘Forrest Gump’-like life while witnessing and taking part in the journeys of some of the most extraordinarily talented people the world has ever seen. I’m constantly pinching myself and asking ‘how did I get here?’”

    The exit from management coincided with a split from Bieber which turned contemptuous, as THR reported in April, due to financial consequences triggered by the cancelation of Bieber’s Justice tour in 2022. In not fulfilling his contractual obligation to AEG (the tour’s promoter) and completing the concert dates, for which he received a $40 million advance, Bieber was left owing more than $20 million to AEG. Then-manager Braun, through his company, covered what was owed in the form of a loan at a highly favorable (to Bieber) rate. In addition, the two were partnered in a number of other businesses including a record label and film projects. Braun also helped secure a $200 million catalog deal for Bieber’s songwriting interests, possibly the largest nest egg in music history for an artist under 30. (Worth noting: Hailey Bieber, who married Justin in 2018, recently sold her Rhode Beauty skincare brand to e.l.f. Beauty for $1 billion; Braun was a seed investor.)

    THR has learned that a settlement between Braun and Bieber is now completed. “Scooter and Justin squashed their issues and are in a good place,” says a source who adds that Braun’s last act at HYBE was to close the book on the squabble and “leave the company, and Justin, in a good position.”

    Reps for Bieber declined to comment on the settlement.

    Stepping into the CEO position in Braun’s place and leading all day-to-day duties is Isaac Lee, who has been chairman of HYBE Latin America since November of 2023. Lee’s new title is chairman and CEO of HYBE Americas. In addition to running HYBE’s operations in Mexico, Miami, and Medellin, Lee will also have oversight of Nashville-based Big Machine Label Group (BMLG) and Quality Control Media Holdings, headquartered in Atlanta.

    While Braun’s next move is unclear, HYBE chief Bang Si-Hyuk commented, “Scooter has been an extraordinary partner, a visionary executive, and a true catalyst for cultural exchange. His contributions have been vital in establishing our ambitious presence in the U.S. market. I am deeply grateful for his leadership, his astute instincts and his unwavering passion for artists. We wish him immense success in his exciting next chapter and look forward to continuing our partnership in executing HYBE’s global vision.”

    Braun also remains one of HYBE’s largest individual shareholders. In announcing his new role, Braun said: “Being a part of HYBE and witnessing its remarkable growth has been one of the most inspiring chapters of my professional journey. Chairman Bang is a true visionary and a musical genius. What he has built with HYBE is unparalleled. I am incredibly proud of our collective accomplishments and look forward to supporting Chairman Bang and CEO Jason Jaesang Lee in their continued success as I step into what’s next.”

    Continue Reading

  • An inside look at Meta’s transition from C to Rust on mobile

    An inside look at Meta’s transition from C to Rust on mobile

    Have you ever worked is legacy code? Are you curious what it takes to modernize systems at a massive scale?

    Pascal Hartig is joined on the latest Meta Tech Podcast by Elaine and Buping, two software engineers working on a bold project to rewrite the decades-old C code in one of Meta’s core messaging libraries in Rust. It’s an ambitious effort that will transform a central messaging library that is shared across Messenger, Facebook, Instagram, and Meta’s AR/VR platforms.

    They discuss taking on a project of this scope – even without a background in Rust, how they’re approaching it, and what it means to optimize for ‘developer happiness.’

    Download or listen to the episode below:

    You can also find the episode wherever you get your podcasts, including:

    The Meta Tech Podcast is a podcast, brought to you by Meta, where we highlight the work Meta’s engineers are doing at every level – from low-level frameworks to end-user features.

    Send us feedback on Instagram, Threads, or X.

    And if you’re interested in learning more about career opportunities at Meta visit the Meta Careers page.


    Continue Reading

  • US set new record with 21 commercial launches in June, FAA says

    US set new record with 21 commercial launches in June, FAA says

    Private spaceflight continues its upward trajectory.

    American companies launched 21 commercial space missions in June 2025, which was a new record for a single month, according to the Federal Aviation Administration (FAA).

    Continue Reading

  • Jennifer Aniston to Lead ‘I’m Glad My Mom Died’ Series at Apple TV

    Jennifer Aniston to Lead ‘I’m Glad My Mom Died’ Series at Apple TV

    If you purchase an independently reviewed product or service through a link on our website, The Hollywood Reporter may receive an affiliate commission.

    Jennifer Aniston has lined up another series at Apple TV+.

    The star and executive producer of The Morning Show will lead a series inspired by Jennette McCurdy’s memoir I’m Glad My Mom Died at the streamer. McCurdy is adapting her book alongside Ari Katcher (Ramy, Jerrod Carmichael Reality Show), and the two will serve as co-showrunners. Aniston is also an executive producer.

    Former iCarly star McCurdy’s book, details the relationship she had with her abusive mother and the road to recovery she took following her mother’s death in 2013. I’m Glad My Mom Died became an instant bestseller after it was published in 2022.

    “I’ve been so touched by how much the emotional thrust of the story has connected with people, which I see as being my relationship with my mom,” McCurdy told The Hollywood Reporter soon after the book was released. “That’s an important and complicated relational dynamic to explore, and to see that people are responding to it has been amazing. And to see people responding to the humor of it and the aspect of exploring eating disorders and complicated grief, it’s really been incredible.”

    The series is described as a dramedy that will center on “the codependent relationship between an 18-year-old actress in a hit kids’ show, and her narcissistic mom who relishes in her identity as a starlet’s mother,” the show’s logline reads. Aniston will play the mother.

    Aniston also has the fourth season of The Morning Show on deck at Apple TV+. The series is set to return Sept. 17, with a two-year time jump following the events of season three in 2023.

    Apple Studios is producing the series based on I’m Glad My Mom Died. McCurdy and Katcher are co-showrunners and will executive produce with Aniston (via her Echo Films); Sharon Horgan and Stacy Greenberg of Merman Productions; Dani Gorin, Tom Ackerley and Josey McNamara of LuckyChap; and Jerrod Carmichael and Erica Kay.

    Aniston is repped by CAA, Lighthouse Management & Media and Hansen Jacobson; McCurdy,by CAA, Jill Fritzo PR and Hansen Jacobson; Horgan, by United Agents in the U.K. WME in the U.S. and Nelson Davis; LuckyChap, by Entertainment 360, CAA, Narrative and attorney Jeff Bernstein; Katcher, by WME, Entertainment 360, and Ziffren Brittenham; and Carmichael, by WME, Entertainment 360 and Johnson Shapiro.

    Continue Reading

  • Kazakhstan bans face coverings in public places – World

    Kazakhstan bans face coverings in public places – World

    Kazakh President Kassym-Jomart Tokayev signed a law on Monday prohibiting individuals from wearing clothing in public places that covers their faces, joining a trend in several Central Asian countries to restrict forms of Islamic dress.

    The text of the law says clothing that “interferes with facial recognition” will be banned in public, with exemptions for medical purposes, in adverse weather conditions and at sporting and cultural events.

    The legislation, one in a series of wider amendments signed into law on Monday, does not explicitly mention religion or types of religious dress.

    Tokayev has previously praised the legislation as an opportunity to celebrate ethnic identity in Kazakhstan, a majority-Muslim country and former Soviet republic.

    “Rather than wearing face-concealing black robes, it’s much better to wear clothes in the national style,” he was quoted by Kazakh media as saying earlier this year.

    “Our national clothes vividly emphasise our ethnic identity, so we need to popularise them comprehensively.”

    Other Central Asian countries have introduced similar laws in recent years.

    Police in Kyrgyzstan have conducted street patrols to enforce their ban on the niqab face veil, according to local media reports. In Uzbekistan, violating the niqab statute carries a fine of over $250. Tajik President Emomali Rakhmon signed a ban on wearing clothing in public that is “alien to national culture”.

    Continue Reading

  • Threads launches its own DM inbox, as app moves further away from Instagram

    Threads launches its own DM inbox, as app moves further away from Instagram

    Instagram Threads is rolling out users’ most-requested feature to date: the ability to message people directly, without having to switch to another app, like Instagram. The company said direct messages (DMs) will begin rolling out to users globally beginning on Tuesday, alongside a new visual element called highlighter.

    The latter will emphasize interesting perspectives and conversations, Meta says, starting with Trending Topics.

    At launch, Threads DMs offer a basic set of features. They’ll support one-on-one chats, preset emoji reactions, the ability to report spam, and mute DMs (as on Instagram). Other features, like group messaging, inbox filters, and more advanced message controls, will arrive in a later release.

    That means today, you can’t block a follower or mutual from messaging you — you can only block them on Threads, which will also block them on Instagram. To control who can message you, you have to choose whether or not you follow the user.

    At launch, DMs will be available in most markets where Threads is available, except for Japan, Australia, the U.K., and the E.U.

    With the addition of DMs, Threads becomes more competitive with other text-first social apps like X and Bluesky, where users can engage with one another directly or even in group chats, as in X’s case.

    However, while X is working on encrypted direct messages within X Chat, Threads has no intention of tightly securing its private messaging feature.

    Image Credits:Meta/Threads

    “We’re not encrypting our DMs,” said Emily Dalton Smith, Threads VP of Product. “It’s really about just connecting directly and talking to people about whatever is happening now, which I think makes encryption less core to the experience.”

    Instead, she said that DMs are meant to build on the community people have created in the public space on Threads — a network that’s shaping up to be entirely different from its parent app, Instagram, Smith pointed out.

    Image Credits:Meta/Threads

    “One thing that’s been particularly exciting is that we have seen that people are building their own graphs on Threads,” she said. “They’re building up what we think of as an interest graph that is new and distinct from the social graph that underlies their account on Instagram.”

    Despite having been built on top of Instagram’s social graph, over a third of the people who come to Threads daily have less than a 50% overlap between their Instagram connections and Threads connections, Meta said.

    “Instagram is really for creativity and Threads is really for perspectives,” Smith noted.

    The company also found that users are following different sets of people across the two apps, Instagram and Threads, and are engaging in different interests and conversations.

    Because of this growing disconnect between the apps, Meta aims to test other ways for people to use Threads without an Instagram account.

    For instance, it’s testing the ability for users to log in with their Facebook account in Europe or create a Threads-only account. It’s also testing the ability to use Threads from the web while not logged in at all.

    Image Credits:Meta/Threads

    The Threads creator community is unique, too. Although it may include those who are popular creators on other platforms, some have become creators on Threads itself. One example is David Rushing, a passionate fan who built up the NBA Threads community.

    Smith said Threads would like to make it easier for its users to find communities like this and others, and this is an important part of the app’s upcoming roadmap.

    On this front, Threads initially introduced tags (like hashtags without the hash # symbol) to organize conversations. It then created topic feeds so you could see everything that was being discussed around that area of interest. Now, the focus will be on identifying the people who are active and top contributors within a community.

    Threads expects to show more suggested users to follow in search and recommendations over the next couple of months, Smith said.

    The new highlight feature could also help here.

    While today, the feature will highlight trending topics related to the content you are reading while scrolling your For You feed, over time, Threads could highlight perspectives from users or active conversations that you might want to jump into, including within various topic feeds.

    There are currently no other plans to monetize Threads beyond ads, Smith confirmed, even though Meta has an AI feature that could be integrated into the experience the way xAI’s AI chatbot, Grok, is used to sell X Premium subscriptions.

    Instead, Meta is first focused on getting ads right, while using AI to power things in the background, like trending topics’ headlines and summaries, for instance.

    That doesn’t mean the team will rule out AI features further down the road.

    “We consider, probably, all ideas,” Smith said, “but we’re really just building on what our community tells us and trying to prioritize such a small and growing app.”

    Threads is not small, to be clear; the app has 350 million monthly active users, far more than newcomers like Bluesky, which has 37 million registered users. But compared with Meta’s family of apps, where user bases are counted in billions, Threads still has much to prove to its corporate parent.

    Ahead of the global launch, DMs were tested earlier this month in a few markets, including Hong Kong, Thailand, Argentina, and Brazil.

    Continue Reading